Last Updated : May 22, 2018
Details
FilesGeneric Name:
Nivolumab
Project Status:
Complete
Therapeutic Area:
classical Hodgkin Lymphoma (cHL) after failure of ASCT
Manufacturer:
Bristol-Myers Squibb
Brand Name:
Opdivo
Project Line:
Reimbursement Review
Project Number:
PC0120-000
NOC Status at Filing:
Pre NOC
Strength:
10 mg/mL
Tumour Type:
Lymphoma
Indications:
classical Hodgkin Lymphoma after failure of ASCT
Funding Request:
For the treatment of adult patients with classical Hodgkin Lymphoma (cHL) that has relapsed or progressed after autologous stem cell transplantation (ASCT) and brentuximab vedotin, or 3 or more lines of systemic therapy including ASCT
Pre Noc Submission:
Yes
Sponsor:
Bristol-Myers Squibb
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Not Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : May 22, 2018